Target therapy in HER2-overexpressing breast cancer patients

OMICS A Journal of Integrative Biology

Volumn 15, Issue 6, 2011, Pages 363-367

  Amodio, Rosalba ^a   Zarcone, Maurizio ^b,c   Cusimano, Rosanna ^a,d   Campisi, Ildegarda ^b   Dolcemascolo, Cecilia ^b   Traina, Adele ^b,c   Agostara, Biagio ^b   Romano, Nino ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b ARNAS Civico   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Department of Epidemiology of ASL6 ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; INTERLEUKIN 10; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA BARCODING; GENE FREQUENCY; GENE INTERACTION; GENETIC ALGORITHM; GENOTYPE; HUMAN; HUMAN TISSUE; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 79958754281     PISSN: 15362310     EISSN: 15362310     Source Type: Journal    
DOI: 10.1089/omi.2010.0125     Document Type: Article

References (16)

1. Andersson, M., Inbar, M., Lichinitser, M., et al. (2005). Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353, 1659-1672. (Pubitemid 41464705)
2. Bender, L.M., and Nahta, R. (2008). Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci 13, 3906-3912. (Pubitemid 351594668)
3. Coussens, L., Yang-Feng, T.L., Liao, Y.C., et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132-1139. (Pubitemid 16169997)
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717.
5. Huang, X., Gao, L., Wang, S., et al. (2010). Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin Cancer Res 70, 1204-1214.
6. Joensuu, H., Kellokumpu-Lehtinen, P.L., Bono, P., et al. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzu-mab for breast cancer. N Engl J Med 354, 809-820. (Pubitemid 43290919)
7. Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation-from incomplete observations. J Am Stat Assoc 53, 457-481.
8. Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353, 1659-1672. (Pubitemid 41464705)
9. Romond, E.H., Perez, E.A., Bryant, J., et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353, 1673-1684. (Pubitemid 41464706)
10. Roukos, D.H. (2010). Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28, e279-280.
11. Sant, M., Allemani, C., Sieri, S., et al. (2007). Salad vegetables dietary pattern protects against HER-2-positive breast cancer: a prospective Italian study. Int J Cancer 121, 911-914. (Pubitemid 47106225)
12. Slamon, D.J., Clark, G.M., Wong, S.G., et al. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182. (Pubitemid 17231334)
13. Slamon, D.J., Godolphin, W., Jones, L.A., et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712. (Pubitemid 19147683)
14. Sorlie, T., Tibshirani, R., Parker, J., et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100, 8418-8423. (Pubitemid 36842560)
15. Working AIRTUM Group. (2009). Monografia Il tumore della mammella nella Regione Siciliana Dati epidemiologici per la prevenzione e il governo clinico. Epidemiol Prev 33(Suppl 1), 43-49.
16. Zarcone, M., Amodio, R., Campisi, I., et al. (2009). Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features of incident cases, Palermo Province, 2002-2004. Ann N Y Acad Sci 1155, 222-226.